Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Laryngeal squamous cell carcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Laryngeal squamous cell carcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Oropharyngeal squamous cell carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
21 July 2026
Oropharyngeal squamous cell carcinoma indication strategy report covering epidemiology, PD-1 biology, active trials, competition and deal signals using PatSnap...
Latest Hotspot
8 min read
Oral squamous cell carcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Oral squamous cell carcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Salivary duct carcinoma Indication Strategy Report 2026: HER2, Trials and Deals
21 July 2026
Salivary duct carcinoma indication strategy report covering epidemiology, HER2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Adenoid cystic carcinoma Indication Strategy Report 2026: MYB, Trials and Deals
21 July 2026
Adenoid cystic carcinoma indication strategy report covering epidemiology, MYB biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Endometrial stromal sarcoma Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Endometrial stromal sarcoma indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Uterine leiomyosarcoma Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Uterine leiomyosarcoma indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Mucinous ovarian carcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
21 July 2026
Mucinous ovarian carcinoma indication strategy report covering epidemiology, KRAS biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Ovarian clear cell carcinoma Indication Strategy Report 2026: ARID1A, Trials and Deals
21 July 2026
Ovarian clear cell carcinoma indication strategy report covering epidemiology, ARID1A biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Ivonescimab Biologics Sequence Review Report 2026: PD-1×VEGF Similarity and Patent-Risk Signals
21 July 2026
A Biology Modality MCP review of Ivonescimab (AK112/SMT112), covering its PD-1×VEGF sequence architecture, full-chain similarity hits, pairwise alignments, patent families and diligence priorities.
Latest Hotspot
8 min read
Low-grade serous ovarian cancer Indication Strategy Report 2026: MEK1, Trials and Deals
21 July 2026
Low-grade serous ovarian cancer indication strategy report covering epidemiology, MEK1 biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Gestational trophoblastic neoplasia Indication Strategy Report 2026: VEGF-A, Trials and Deals
21 July 2026
Gestational trophoblastic neoplasia indication strategy report covering epidemiology, VEGF-A biology, active trials, competition and deal signals using PatSnap...